Glycan biomarker discovery
Mass-spectrometry glycan profiling underpins the discovery of disease-associated glycan changes, but candidate markers generally require independent validation and standardized workflows before clinical application.1
Glycome Atlas
method
Also known as glycan mass spectrometry, released-glycan MS, MS glycan profiling
Plain-language answer
Mass-spectrometry glycan analysis weighs sugar molecules very precisely to work out what they are made of. Sugar chains are usually cut off their parent proteins or lipids first, then measured by their mass, and often broken into pieces so the instrument can read the order of the building blocks.1
This is the workhorse method for reading glycan structures, and it lets researchers compare healthy and diseased samples in detail. Because sugar patterns change in cancer, inflammation, and many other conditions, sensitive mass measurement is central to finding and confirming glycan biomarkers.1
Technical detail
Mass-spectrometry glycan analysis determines glycan composition and, through tandem fragmentation, partial sequence and branching, typically from glycans enzymatically or chemically released from glycoproteins and glycolipids, using platforms such as MALDI-TOF and LC-ESI-MS often preceded by permethylation or other derivatization.1
MALDI-TOF provides rapid profiling of released glycan mixtures, while LC-ESI-MS couples online chromatographic separation with electrospray ionization to resolve closely related structures and isomers before detection. Derivatization such as permethylation stabilizes labile residues, improves ionization, and helps distinguish linkage-related fragments.1
Tandem mass spectrometry fragments a selected glycan ion to generate diagnostic product ions that report composition and, in combination with retention behavior or exoglycosidase digestion, help infer branching and linkage. Even so, complete de novo assignment of linkage and anomeric configuration usually requires orthogonal methods.1
Human relevance
Mass-spectrometry glycan profiling underpins the discovery of disease-associated glycan changes, but candidate markers generally require independent validation and standardized workflows before clinical application.1
Continue exploring
References